ライフサイエンスコーパス: resectable

1 Thirty-nine tumors never became resectable.

2 after PVE, of whom 3 patients (11%) were not resectable.

3 se; however, tumors may remain surgically un-resectable.

4 local/in-transit or nodal, asymptomatic, or resectable.

5 274 included patients, 46.4% were borderline resectable, 25.5% locally advanced, and 83.2% had pancre

6 ith melanoma diagnosed as having potentially resectable abdominal metastases before (1969-2003) and a

7 c immune-inflammation index in patients with resectable adenocarcinoma of the gastroesophageal juncti

8 le-center, single-arm study of patients with resectable adenocarcinoma of the pancreas who were treat

9 nosed with stage II to III locally advanced, resectable adenocarcinoma of the rectum with a distal tu

10 We randomly assigned patients with resectable adenocarcinoma of the stomach, esophagogastri

11 overed in this review are as follows: who is resectable; adjunctive surgical techniques that can impr

12 If the disease becomes resectable, adjuvant treatment should follow surgery.

13 However, in some cases, tumors seem resectable after chemotherapy through aggressive use of

14 patients were aged 18 years or older and had resectable American Joint Committee on Cancer-defined st

15 nd 43 metastatic) and 65 had lower stage (48 resectable and 17 borderline resectable) tumors.

16 -Biliary Association Consensus Conference on Resectable and Borderline Resectable Disease.

17 ll patients undergoing upfront resection for resectable and borderline-resectable PDAC from 10/2001 t

18 The primary goal of care for patients with resectable and borderline-resectable tumors is cure, fac

19 with neoadjuvant chemotherapy in borderline-resectable and locally advanced PDAC RESULTS:: In the re

20 stem, blood samples from patients with local resectable and metastatic pancreatic ductal adenocarcino

21 as well as in the diagnosis and treatment of resectable and nonresectable PNETs.

22 s with metastatic disease, and management of resectable and potentially resectable metastases-and how

23 n (SLT) strategy was conceived for initially resectable and transplantable (R&T) hepatocellular carci

24 f nelfinavir chemoradiotherapy in borderline resectable and unresectable pancreatic cancer.

25 ls that impact mesothelioma treatment in the resectable and unresectable settings, discuss the impact

26 he setting of locally advanced disease--both resectable and unresectable.

27 y (n = 80) or whose lesions were potentially resectable and who refused surgery (n = 19) were include

28 astases that are unresectable rendering them resectable, and decrease postoperative recurrence rates

29 presenting with distant metastases, are not resectable, and have a 5-year survival rate of close to

30 s where the seizure focus might present as a resectable area.

31 y 31, 2010, and stratified to 1 of 3 groups: resectable (arm A), limited metastatic (arm B), or exten

32 Patients whose tumors remained resectable at restaging proceeded to operation and subse

33 four categories based on extent of disease: resectable, borderline resectable, locally advanced, and

34 tors can predict resectability of borderline resectable (BR) and locally advanced (LA) pancreatic duc

35 urvival outcomes in patients with borderline resectable (BR) or locally advanced (LA) pancreatic duct

36 Patients with resectable BRAF-mut CRLM are rare among patients selecte

37 who preoperatively appeared to be marginally resectable but had a tumor-free left lateral lobe.

38 s have shown significant promise in treating resectable but high-risk clinical scenarios.

39 ass and cervical adenopathy were technically resectable but that resection carried a substantial risk

40 CLC that was deemed locally to be surgically resectable by a multidisciplinary clinical team, and an

41 proven non-small cell lung cancer considered resectable by standard imaging, including routine preope

42 copy prior to laparotomy in patients with CT-resectable cancer appears to be cost-effective in pancre

43 nvolving patients 18 to 75 years of age with resectable cancer of the middle or lower third of the es

44 The greatest need was for patients with resectable cancer.

45 eased in comparison to patients with clearly resectable cancers at the time of presentation.

46 Patients aged 18 to 75 years with resectable cancers of the middle or lower third of the e

47 age; and 38.2% (3,644/9559) with potentially resectable cancers were classified as "not offered surge

48 NLR, PLR, LMR and GPS/mGPS in patients with resectable cancers.

49 ancer, representing approximately 10% of all resectable cases.

50 Perioperative FOLFOX for locally advanced resectable CC is feasible with an acceptable tolerabilit

51 To establish a mouse model of resectable cholangiocarcinoma including the most frequen

52 e, OS is comparable with liver resection for resectable CLMs and survival after repeat liver transpla

53 predicted the status of the nodal basin for resectable colon cancer and, therefore, could be extensi

54 rial of neoadjuvant chemotherapy in advanced resectable colon cancer, improvement of the plane of dis

55 conventional histopathology in patients with resectable colon cancer.

56 isease and improves staging in patients with resectable colon cancer.

57 Ninety patients with resectable colorectal cancer metastatic to the liver und

58 arch 2001 and August 2006, 152 patients with resectable colorectal cancer were enrolled in the trial.

59 s 12, 13, and 61) resectable or suboptimally resectable colorectal liver metastases and a WHO perform

60 exon 2 wild-type resectable or suboptimally resectable colorectal liver metastases were randomised i

61 Patients with resectable colorectal liver metastases were randomly ass

62 multicentre New EPOC trial in patients with resectable colorectal liver metastasis showed a signific

63 ab to standard chemotherapy in patients with resectable colorectal liver metastasis.

64 rd of care in selected patients with limited resectable CPM.

65 n 2001 and 2007, 253 evaluable patients with resectable CRC were enrolled.

66 c resection can improve OS for patients with resectable CRHM.

67 Patients with surgically resectable disease (< or = cT4aN0M0) received a total of

68 sociated with poor survival in patients with resectable disease (HR: 1.37; 95% CI: 1.15-1.63) but not

69 y to detect CTCs in PDAC patients with local resectable disease (mean = 11 CTCs per mL).

70 diagnosed patients with hepatoblastoma have resectable disease at diagnosis.

71 ith pancreatic and periampullary cancer with resectable disease based on CT scanning.

72 nocarcinoma who otherwise are viewed to have resectable disease but have preoperative findings of ext

73 l for patients with resectable or borderline-resectable disease may be warranted.

74 ividuals undergoing treatment for surgically resectable disease may experience recurrence near the re

75 ucleic acids to improve surgical outcomes in resectable disease, augment current therapies, expand dr

76 cytoreductive surgery, and with potentially resectable disease, may receive either neoadjuvant chemo

77 For patients with resectable disease, modified 5-fluorouracil, leucovorin,

78 However, only 20% of patients present with resectable disease.

79 nsus Conference on Resectable and Borderline Resectable Disease.

80 as 43% (95% CI, 28% to 58%) in patients with resectable disease.

81 patients were enrolled, and of these 43 had resectable disease.

82 r and increasing cure rates among those with resectable disease.

83 ce between surgery and CRT for patients with resectable disease.

84 ly from 100 patients who were judged to have resectable EC.

85 dependent prognostic factor in patients with resectable EC.

86 apy is established in the management of most resectable esophageal and esophagogastric junction adeno

87 Y BACKGROUND DATA: The optimal treatment for resectable esophageal cancer is unknown.

88 effective strategy in improving survival of resectable esophageal cancer.

89 a primary treatment option for patients with resectable esophageal cancer.

90 f occult lymph node metastases in surgically resectable esophageal cancers.

91 rapy as a standard of care for patients with resectable esophagogastric cancer.

92 ll beta-cells or only in beta-cells within a resectable focal lesion.

93 In the CRITICS trial, patients with resectable gastric cancer were randomized to receive pre

94 For surgically resectable gastric cancer, removal of 15 or more lymph n

95 capecitabine chemotherapy for patients with resectable gastric, oesophagogastric junction, or lower

96 peri-operative chemotherapy in patients with resectable gastric, oesophagogastric junction, or lower

97 estimate disease-specific survival (DSS) for resectable gastroesophageal (GE) junction and gastric ad

98 t adverse prognostic factor in patients with resectable gastroesophageal adenocarcinomas with and wit

99 ong MMRD, MSI, and survival in patients with resectable gastroesophageal cancer randomized to surgery

100 Patients with resectable gastrointestinal stromal tumors (GISTs) might

101 In patients with resectable GE junction and gastric adenocarcinoma, pretr

102 ab in 35 patients with recurrent, surgically resectable glioblastoma.

103 to render initially unresectable metastases resectable has increased the percentage of patients elig

104 nge, 53-79 years; mean age, 66.2 years) with resectable HCC (diameter, 2.9-6.0 cm; mean, 4.2 cm) unde

105 Among patients with potentially resectable hepatic metastases of colorectal adenocarcino

106 by Radiotherapy Versus Radiochemotherapy for Resectable High Risk Squamous Cell Carcinoma of the Head

107 At diagnosis, patients age </= 40 years with resectable high-grade osteosarcoma were registered.

108 r randomized phase II trial in patients with resectable high-risk T3, T4, and/or N2 CC on baseline co

109 Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or you

110 have developed a murine model of single, R0-resectable ICC with favorable characteristics for the st

111 nts whose tumors were reevaluated and deemed resectable in the last week of radiotherapy were randoml

112 t approach that includes surgical removal if resectable, in combination with multiagent chemotherapy

113 l was conducted, assigning 112 patients with resectable intrathoracic esophageal cancer to either RAM

114 en June 2009 and March 2011, patients with a resectable intrathoracic esophageal carcinoma, including

115 ate the worse outcomes seen in patients with resectable KRAS-MUT CRLM.

116 ate the worse outcomes seen in patients with resectable KRAS-MUT CRLM.

117 of patients with locally advanced/borderline resectable (LA/BR) pancreatic ductal adenocarcinoma (PDA

118 distinction between patients presenting with resectable lesions (neoadjuvant) versus patients present

119 Eighty-eight patients had resectable lesions according to CT angiographic criteria

120 g unresectable liver metastases, but not for resectable lesions, for which adjuvant chemotherapy is p

121 For resectable lesions, studies on neoadjuvant chemotherapy

122 ery alone for patients with initially 1 to 4 resectable liver metastases from colorectal cancer (CRC)

123 after 1 cycle of treatment in patients with resectable liver metastases from colorectal cancer, with

124 Some suggest that resectable liver metastases, in the absence of high-risk

125 the survival for a patient with a solitary, resectable liver metastasis is better than that for a pa

126 and enables curative resection of marginally resectable liver tumors or metastases in patients that m

127 ntation protocols for curative intent in non-resectable localized disease have been described.

128 on extent of disease: resectable, borderline resectable, locally advanced, and metastatic; patient co

129 uperior oncologic outcomes for patients with resectable lung cancer.

130 Improvements in outcomes for patients with resectable lung cancers have plateaued.

131 for survival in future neoadjuvant trials of resectable lung cancers.

132 rican Joint Committee on Cancer stage IIA-IV resectable MCC received >= 1 nivolumab dose.

133 virus-associated cancer types, patients with resectable MCC received nivolumab 240 mg intravenously o

134 of anti-PD-1 in the neoadjuvant setting for resectable MCC.

135 options for regionally advanced, "borderline-resectable" MCC.

136 ant differences in survival observed between resectable mesenteric lymph nodes versus unresectable ma

137 at have been made in surgical techniques for resectable metastases and the impact of modern chemother

138 h colorectal cancer treated by surgery, with resectable metastases based on CT scans of the chest, ab

139 and management of resectable and potentially resectable metastases-and how these strategies can be ap

140 In resectable MRD, PNB-guided surgery prevented local recur

141 median age, 64 years; 27 men, 17 women) with resectable (n = 12), unresectable (n = 29), and metastat

142 February, 2017, 280 patients with borderline resectable (n = 18), locally advanced (n = 190), or olig

143 For localized, resectable neuroblastoma without MYCN amplification, sur

144 erapy remains the most advisable therapy for resectable neuroendocrine tumors of the pancreas, there

145 Genomic aberrations of resectable non-MYCN-amplified stage 2 neuroblastomas hav

146 ode involvement in patients with potentially resectable non-small cell lung cancer (NSCLC)?

147 PET) scan after neoadjuvant chemotherapy for resectable non-small-cell lung cancer (NSCLC) is prognos

148 ressed in approximately 35% of patients with resectable non-small-cell lung cancer (NSCLC).

149 vivo) response in patients with early-stage resectable non-small-cell lung cancer (NSCLC).

150 could be a potential neoadjuvant regimen for resectable non-small-cell lung cancer, with a high propo

151 Clinical trials of resectable non-small-cell lung cancers with overall surv

152 Patients with early-stage, resectable, non-small-cell lung cancer (NSCLC) are at ri

153 We investigated the prevalence of OMs in resectable NSCLC and their relationship with survival.

154 of preoperative (induction) chemotherapy in resectable NSCLC demonstrated feasibility and encouragin

155 Among patients with resectable NSCLC treated with neoadjuvant chemotherapy,

156 single option for patients with potentially resectable NSCLC.

157 in an independent cohort of 96 patients with resectable NSCLC.

158 ng utilizing ICG in patients with surgically resectable NSCLC.

159 aminations were performed in 35 patients (36 resectable NSCLCs) between 2009 and 2014.

160 Patients with surgically resectable oesophageal adenocarcinoma classified as stag

161 years and older with histologically proven, resectable oesophagogastric adenocarcinoma from 87 UK ho

162 gery is a standard of care for patients with resectable oesophagogastric adenocarcinoma.

163 Forty-three patients (11.4%) had resectable oligometastatic disease.

164 Preoperative chemoradiotherapy for resectable or borderline resectable pancreatic cancer di

165 phase III trial in 16 centers, patients with resectable or borderline resectable pancreatic cancer we

166 y may improve the radical resection rate for resectable or borderline resectable pancreatic cancer, b

167 a larger, randomized trial for patients with resectable or borderline-resectable disease may be warra

168 91; P = .027) and stage (locally advanced vs resectable or borderline: HR, 1.66; 95% CI, 1.10-2.51, P

169 ; 95% CI, 1.10-2.51, P = .016; metastatic vs resectable or borderline: HR, 2.50; 95% CI, 1.64-3.79; P

170 ients aged 18 years or older with borderline resectable or locally advanced biopsy-proven pancreatic

171 encing strategy for patients with borderline resectable or locally advanced pancreatic adenocarcinoma

172 Of 331 patients with borderline resectable or locally advanced PDAC, 30 achieved a pCR f

173 improve survival in patients with borderline resectable or locally advanced unresectable PDAC receivi

174 en shown to benefit patients with borderline resectable or locally advanced unresectable PDAC.

175 ized (1:1) trial of patients with borderline resectable or locally advanced unresectable PDAC.

176 spective, phase 2 trial of 252 patients with resectable or metastatic gastric or gastroesophageal jun

177 in patients with localized disease, whether resectable or not.

178 Patients with KRAS exon 2 wild-type resectable or suboptimally resectable colorectal liver m

179 with KRAS wild-type (codons 12, 13, and 61) resectable or suboptimally resectable colorectal liver m

180 ng resectability to a definitive answer (ie, resectable or unresectable) when the reports were struct

181 with newly diagnosed stage III (incompletely resectable) or stage IV epithelial ovarian cancer who ha

182 The 9 patients with nonmetastatic, resectable, or borderline-resectable PBCs had a mean of

183 rcalated surgery is the standard of care for resectable OS in those younger than 40 years.

184 In a mouse model of non-resectable ovarian cancer, the cell-loaded nitinol thin

185 34 patients had PD with PV/SMV resection for resectable PA on preoperative staging.

186 The role for neoadjuvant systemic therapy in resectable pancreas adenocarcinoma remains undefined.

187 herapy is worthy of further investigation in resectable pancreas adenocarcinoma.

188 red as preoperative therapy in patients with resectable pancreas adenocarcinoma.

189 so received adjuvant therapy-for early-stage resectable pancreatic adenocarcinoma.

190 patient selection tool, in the management of resectable pancreatic adenocarcinoma.

191 t improve prognostic accuracy in LN-positive resectable pancreatic adenocarcinoma.

192 workup of preoperative SCPN in patients with resectable pancreatic adenocarcinoma.

193 umor cells (CTCs) for patients with presumed resectable pancreatic and periampullary cancers.

194 ollected at diagnosis from 129 subjects with resectable pancreatic cancer and 275 controls (100 healt

195 cal resection for patients with early-stage, resectable pancreatic cancer are associated with socioec

196 Comparison of resectable pancreatic cancer cases to subjects with chro

197 emoradiotherapy for resectable or borderline resectable pancreatic cancer did not show a significant

198 ly, it appears that a third of patients with resectable pancreatic cancer do not receive an operation

199 or distinguishing newly diagnosed cases with resectable pancreatic cancer from healthy controls (64%

200 -institutional neoadjuvant phase II study in resectable pancreatic cancer is planned.

201 Current treatment recommendations for resectable pancreatic cancer support upfront resection a

202 ters, patients with resectable or borderline resectable pancreatic cancer were randomly assigned to r

203 his has led to the definition of "borderline resectable pancreatic cancer"--a new clinical category t

204 resection rate for resectable or borderline resectable pancreatic cancer, but the overall benefit is

205 ort the preoperative treatment of borderline resectable pancreatic cancer, no prospective, quality-co

206 e-inflammation index (SIII) in patients with resectable pancreatic cancer, using cancer-specific surv

207 ss discriminatory power for the detection of resectable pancreatic cancer, with high specificity and

208 burden associated with treatment options for resectable pancreatic cancer.

209 bility and overall survival of patients with resectable pancreatic cancer.

210 biomarkers for the noninvasive detection of resectable pancreatic cancer.

211 reasingly used in patients with (borderline-)resectable pancreatic cancer.

212 of gemcitabine-based preoperative therapy in resectable pancreatic cancer.

213 fter resection in patients with (borderline-)resectable pancreatic cancer.

214 ims to compare both treatment strategies for resectable pancreatic cancer.

215 and surgery-first with adjuvant therapy for resectable pancreatic cancer.

216 atients was different than that reported for resectable pancreatic cancers, implying a biologic basis

217 The optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and th

218 ic significance of the SIII in patients with resectable pancreatic ductal adenocarcinoma (PDAC) and t

219 jor shift in the management of patients with resectable pancreatic ductal adenocarcinoma (PDAC) when

220 tandard of care in the adjuvant treatment of resectable pancreatic ductal adenocarcinoma (PDAC).

221 Transgenic mice with resectable pancreatic tumors might be promising tools to

222 cantly higher in nonresectable (46%) than in resectable patients (11.7%), P < 0.001.

223 yzing all patients (P = 0.002) and analyzing resectable patients (P < 0.001).

224 Cs, 31% of the nonresectable and 9.1% of the resectable patients (P = 0.001).

225 urvival estimates differed significantly for resectable patients exposed to low doses (50 to 150 mg/m

226 Resectable patients underwent surgery 4 to 6 weeks after

227 val that appears to be superior than that of resectable patients who go directly to surgery.

228 Forty-four resectable patients with MPM underwent pleurectomy, foll

229 val rates were 73% for all patients, 94% for resectable patients, 76% for borderline-resectable patie

230 for resectable patients, 76% for borderline-resectable patients, and 47% for unresectable patients.

231 d resectable, three (33%) of nine borderline-resectable patients, and one (7%) of 14 unresectable pat

232 but not associated with clinical outcome in resectable patients.

233 ith nonmetastatic, resectable, or borderline-resectable PBCs had a mean of 83.2 CTCs/7.5 mL portal ve

234 is recommended for patients with borderline resectable PC and, at some centers, neoadjuvant therapy

235 t therapy has been extended to patients with resectable PC as well.

236 lear that adherence to strict definitions of resectable PDA is challenging; (2) Patients can tolerate

237 icant increase in survival for patients with resectable PDA.

238 ed in a neoadjuvant/perioperative format for resectable PDA.

239 improve survival in patients with primarily resectable PDAC after R0 resection.

240 ront resection for resectable and borderline-resectable PDAC from 10/2001 to 12/2011 were identified

241 Curative-intent surgery for potentially resectable PDAC is underutilized in the United States.

242 In all, 590 patients with resectable PDAC were included.

243 actors are well documented for patients with resectable PDAC, but have not been described in detail f

244 In a transgenic mouse model of resectable PDAC, we investigated the coordinated activat

245 tive gemcitabine-based chemoradiotherapy for resectable PDAC.

246 anced the performance of the panel to detect resectable PDAC.

247 matched blood samples from 12 patients with resectable PDAC.

248 fic survival and recurrence in patients with resectable PDAC.

249 t study randomizes patients with potentially resectable PHC and biliary obstruction between preoperat

250 infiltration of total T cells compared with resectable primary PDACs, suggesting that metastatic PDA

251 ng a better definition of which patients are resectable, randomized studies comparing perioperative w

252 tic disease and whose disease was considered resectable received one of four prospectively randomized

253 oradiotherapy (CT-RT) regimens in T3-4 Nx M0 resectable rectal cancer.

254 with worse survival and aggressive rarely re-resectable recurrences.

255 fter ILI with ability to identify surgically resectable recurrent disease in these high-risk patients

256 on-small-cell lung cancer (NSCLC), even when resectable, remains poor.

257 Eighteen patients with surgically resectable SCUC received neoadjuvant treatment with a me

258 s of neoadjuvant chemotherapy for surgically resectable SCUC.

259 s, for which chemotherapy is used to reach a resectable situation (downsizing).

260 e target detectable pancreatic neoplasms are resectable stage I pancreatic ductal adenocarcinoma and

261 Eligibility criteria included resectable stage I to III cancer of the mid-/distal-esop

262 with non-small-cell lung cancer present with resectable stage IB-IIIA disease, and although periopera

263 oadjuvant chemoradiotherapy in patients with resectable stage II-III rectal cancer.

264 surgery with definitive chemoradiotherapy in resectable stage III disease after induction.

265 imen and optimal management of patients with resectable stage III disease.

266 PFS rates in randomly assigned patients with resectable stage III non-small-cell lung cancer were exc

267 nti-PD-1 treatment is effective in high-risk resectable stage III/IV melanoma.

268 py followed by CCR for organ preservation in resectable stage III/IVA and IVB larynx and oropharynx (

269 platinum-based chemotherapy in patients with resectable stage IIIA NSCLC.

270 safety of neoadjuvant chemoimmunotherapy for resectable stage IIIA NSCLC.

271 Eligibility required resectable stage T2N+, or T3-T4N0-3M0 biopsy-proven squa

272 tively successful, detecting most PDACs at a resectable stage.

273 ntify precursor lesions and PDAC at an early resectable stage.

274 among the minority of patients diagnosed at resectable stages, systemic clinical management will ine

275 irteen (81%) of 16 patients initially judged resectable, three (33%) of nine borderline-resectable pa

276 In the Phase II borderline-resectable trial (NCI# 01591733) cohort of 32 patients,

277 giopoietin/Tie2 pathway, in a mouse model of resectable triple-negative breast cancer (TNBC).

278 geneity is largely limited to the surgically resectable tumor core lesion while the seeds for recurre

279 Of 44 cases with resectable tumor on CT scan, EUS-FNA avoided thoracotomy

280 59 patients were identified with potentially resectable tumors (pretreatment clinical Stage I: T1N0M0

281 vely; the 2-year OS was 59% in patients with resectable tumors and was 25% in patients with unresecta

282 for patients with resectable and borderline-resectable tumors is cure, facilitated by achieving marg

283 with 5-year survival rates for patients with resectable tumors ranging from 15% to 20%.

284 We randomly assigned patients with resectable tumors to receive surgery alone or weekly adm

285 B tumors, 5-year survival rates were 95% for resectable tumors versus 78% for unresectable mesenteric

286 induction, 161 (65.4%) of 246 patients with resectable tumors were randomly assigned; strata were tu

287 a allows for identification and treatment of resectable tumors with improved survival.

288 urvival (OS), particularly for patients with resectable tumors without extrahepatic disease.

289 atients with rapidly growing or incompletely resectable tumors, so these patients should be managed n

290 of surgical hepatic resection versus RFA for resectable tumors; the utility of RFA for unresectable t

291 lower stage (48 resectable and 17 borderline resectable) tumors.

292 soft tissue with locally advanced disease or resectable tumours requiring extensive surgery, an Easte

293 All cohorts included only patients with resectable tumours, and a formalin-fixed, paraffin-embed

294 recurrence rates in patients with initially resectable tumours.

295 is the treatment of choice in patients with resectable tumours.

296 for patients with GCTB with unresectable and resectable tumours.

297 injectable melanoma that was not surgically resectable were randomly assigned at a two-to-one ratio

298 initially unresectable CRC liver metastases resectable, while at the same time distinguishing betwee

299 1 mutation carriers, and they were generally resectable with good short-term outcomes.

300 atic colorectal cancer (CRC) can be rendered resectable with systemic chemotherapy in approximately 2